Research Topics
Genomes and GenesSpecies | Kenneth A BauerSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Fondaparinux sodium: a selective inhibitor of factor XaK A Bauer
Hematology Section, VA Boston Healthcare System, Beth Israel Deaconess Medical Center, MA, USA
Am J Health Syst Pharm 58:S14-7. 2001..Fondaparinux sodium appears to meet the criteria for an ideal antithrombotic agent: equal or better effectiveness than currently available agents, a low bleeding risk, no need for laboratory monitoring, and once-daily administration...- A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialistKenneth A Bauer
Department of Medicine, VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J South Orthop Assoc 11:197-202. 2002..Fondaparinux has demonstrated its efficacy compared to a widely used low-molecular-weight heparin in a number of thromboprophylaxis trials after major orthopedic surgery and is approved for use in this setting... - Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolismKenneth A Bauer
VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Curr Opin Pulm Med 8:398-404. 2002..Fondaparinux also appears to be a very promising candidate for the treatment of patients with existing VTE... - Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxisKenneth A Bauer
Hematology Division, VA Boston HealthCare System and Beth Deaconess Medical Center, Boston, Massachusetts 02215, USA
Am J Orthop (Belle Mead NJ) 31:4-10. 2002.... - Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitorsKenneth A Bauer
VA Boston Health System, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
Cardiovasc Drug Rev 20:37-52. 2002..In view of these collective findings, fondaparinux is expected to play a major role in the prevention and treatment of venous and arterial thrombotic disease... - Management of thrombophiliaK A Bauer
VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts, USA
J Thromb Haemost 1:1429-34. 2003..Low-intensity warfarin therapy or novel anticoagulants such as oral direct thrombin inhibitors may prove effective strategies for preventing recurrent venous thromboembolism in patients with thrombophilia... - Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgeryK A Bauer
Department of Medicine, Veterans Affairs Boston Healthcare System and Beth Israel Deaconess Medical Center, MA 02215, USA
N Engl J Med 345:1305-10. 2001..Despite thromboprophylaxis, major knee surgery carries a high risk of venous thromboembolism. Fondaparinux, the first of a new class of synthetic antithrombotic agents, may reduce this risk... 
Long-term management of venous thromboembolism: a 61-year-old woman with unprovoked venous thromboembolismKenneth A Bauer
Harvard Medical School, and Beth Israel Deaconess Medical Center, Boston, Massachusetts, Boston, MA 02492, USA
JAMA 305:1336-45. 2011..The case of Ms W, a woman with unprovoked venous thromboembolism and hemorrhagic event while receiving anticoagulation, is used to illustrate clinical decision making to determine ongoing treatment...- Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical proceduresBarbara A Konkle
Department of Medicine, University of Pennsylvannia School of Medicine, Philadelphia, 19104, USA
Transfusion 43:390-4. 2003..For this reason, replacement with AT concentrate has been used when anticoagulation is interrupted. A new recombinant human AT concentrate, produced using transgenic technology, has recently been developed... - Role of thrombophilia in deciding on the duration of anticoagulationKenneth A Bauer
Veterans Administration Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02132, USA
Semin Thromb Hemost 30:633-7. 2004.... - Fondaparinux: a new synthetic and selective inhibitor of Factor XaKenneth A Bauer
Harvard Medical School, Hematology Section, VA Boston Healthcare System, and Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Best Pract Res Clin Haematol 17:89-104. 2004..Other trials have demonstrated that fondaparinux is efficacious in the prevention of VTE in other patient populations at risk of thrombosis and in the treatment of symptomatic VTE... - New anticoagulants: anti IIa vs anti Xa--is one better?Kenneth A Bauer
VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
J Thromb Thrombolysis 21:67-72. 2006..A number of oral direct factor Xa inhibitors as well as other oral direct thrombin inhibitors are in clinical development for the prevention and treatment of thrombosis... - Low intensity warfarin: is it clinically useful in venous thromboembolism management?Kenneth A Bauer
VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Br J Haematol 127:155-8. 2004.... - New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacologyKenneth A Bauer
Department of Medicine, Harvard Medical School, and Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
Chest 124:364S-370S. 2003..Fondaparinux has been approved for use in thromboprophylaxis after major orthopedic surgery, where it has demonstrated its efficacy compared to a low-molecular-weight heparin. Its clinical development in other indications is ongoing... - Timing of postpartum enoxaparin administration and severe postpartum hemorrhageRachel A Freedman
Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
Blood Coagul Fibrinolysis 19:55-9. 2008..Severe postpartum hemorrhage is an infrequent complication when enoxaparin is administered to hemostatically intact women between 5 and 24 h following a vaginal delivery or 12-36 h following cesarean section... - Duration of anticoagulation: applying the guidelines and beyondKenneth A Bauer
Hematology Section, VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, MA 02215, USA
Hematology Am Soc Hematol Educ Program 2010:210-5. 2010..The potential impact of having a nonremovable inferior vena caval filter will also be addressed... - Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patientsOlivier Kocher
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
Am J Clin Pathol 127:68-75. 2007..These results confirm the association between genetic thrombophilia and selected obstetric complications... - New oral anticoagulants in development: potential for improved safety profilesKenneth A Bauer
Hematology Oncology Division, Beth Israel Deaconess Medical Center and VA Boston Healthcare System, Boston, MA, USA
Rev Neurol Dis 7:1-8. 2010..Studies suggest that they provide effective, predictable anticoagulation with a low bleeding risk and will potentially offer an improved clinical profile and wider safety margin compared with currently available therapies... 
The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer sizeJeffrey I Zwicker
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Blood 108:1280-3. 2006....- Reversal of antithrombotic agentsKenneth A Bauer
Department of Medicine, Beth Israel Deaconess Medical Center and VA Boston Healthcare System, Boston, Massachusetts 02215, USA
Am J Hematol 87:S119-26. 2012..This review describes available and future options for the reversal of the effects of anticoagulants, in particular the new oral agents and discusses current management strategies for bleeding events in clinical practice... - Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancyJeffrey I Zwicker
Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
Clin Cancer Res 15:6830-40. 2009..We evaluated the hypothesis that tumor-derived tissue factor-bearing microparticles in plasma contribute to cancer-associated thrombosis... - New anticoagulantsKenneth A Bauer
VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Curr Opin Hematol 15:509-15. 2008..New anticoagulants have been developed that selectively inhibit thrombin or factor Xa, and have predictable dose-response relationships... - Selective inhibition of coagulation factors: advances in antithrombotic therapyKenneth A Bauer
VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Semin Thromb Hemost 28:15-24. 2002..The availability of these agents and the continued development of investigational selective coagulation inhibitors have the potential to improve efficacy and decrease adverse events in patients at risk for VTE... - Assessment of hemostatic risk factors in predicting arterial thrombotic eventsDavid Feinbloom
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
Arterioscler Thromb Vasc Biol 25:2043-53. 2005..However, the data on Factor VII, PAI-1, and platelet receptor polymorphisms are contradictory or lacking... - The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiencyWeei-Yuarn Huang
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Transfusion 44:1562-6. 2004..Doses lower than those used in patients with FVIII inhibitors appear to be effective in the setting of central nervous system hemorrhage... - Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studiesAlexander G G Turpie
Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton, Hamilton, Ontario, Canada L8L 2X2
Arch Intern Med 162:1833-40. 2002..Fondaparinux, the first of a new class of synthetic selective factor Xa inhibitors, may further reduce this risk compared with currently available thromboprophylactic treatments... - Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Jack Hirsh
Henderson Research Centre, Hamilton Civic Hospitals, 711 Concession Street, Hamilton, Ontario, Canada
Chest 133:141S-159S. 2008..Three parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in HIT patients... - New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studiesAlexander G G Turpie
Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
Chest 124:371S-378S. 2003..Fondaparinux has been recently approved for use in thromboprophylaxis after major orthopedic surgery. The clinical development of fondaparinux in other thromboprophylactic indications is ongoing... - Fondaparinux and prevention of venous thromboembolism after orthopaedic surgeryAlexander G G Turpie
Lancet 362:1582-3. 2003 - Hormone replacement therapy and the factor V Leiden mutationKenneth A Bauer
Arterioscler Thromb Vasc Biol 22:879-80. 2002 - Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trialAlexander G G Turpie
Department of Medicine, General Division, Hamilton Health Sciences Corporation, Ontario, Hamilton, Canada
Lancet 359:1721-6. 2002..We aimed to see whether the pentasaccharide fondaparinux, the first drug of a new class of synthetic antithrombotic agents, could reduce this risk to a greater extent than other available treatments... - Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparisonMichael Rud Lassen
Department of Orthopaedics, University Hospital of Copenhagen Hillerød, DK 3400, Hillerød, Denmark
Lancet 359:1715-20. 2002..We aimed to assess the ability of the pentasaccharide fondaparinux, the first of a new class of synthetic antithrombotic agents, to further reduce this risk... - Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzeesArno H M Moons
Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
Thromb Haemost 88:627-31. 2002..These results suggest that rNAPc2 may be a promising therapeutic option to inhibit coagulation activation in patients with sepsis... - Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disordersRichard D Press
Department of Pathology and Medical Genetics, Oregon Health and Science University, Portland 97201, USA
Arch Pathol Lab Med 126:1304-18. 2002..As FVL is currently the most common recognized familial thrombophilia, it is hoped that these recommendations will assist laboratorians and clinicians caring for patients (and families) with this common mutation... - Fondaparinux, the first selective factor Xa inhibitorAlexander G G Turpie
Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
Curr Opin Hematol 10:327-32. 2003..Finally, the efficacy and safety of fondaparinux in the treatment of venous thromboembolism and acute coronary syndromes appears promising... - Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end pointsAlexander G G Turpie
Department of Medicine, Hamilton Health Sciences General Hospital, 237 Barton St East, Hamilton, ON, L8L 2X2, Canada
Chest 126:501-8. 2004.... - Coagulation activation and long-term outcome in acute coronary syndromesDiego Ardissino
Division of Cardiology, Ospedale Niguarda Ca Grande, Milan
Blood 102:2731-5. 2003..25-2.28; RR, 1.35 and 95% CI, 1.11-1.86, respectively). After an episode of acute coronary syndrome, both high and low levels of thrombin generation are predictors of an increased risk of an unfavorable outcome... - FondaparinuxAlexander G G Turpie
Department of Medicine, Hamilton Health Sciences-Hamilton General Hospital and McMaster University, Hamilton, Ontario, Canada
J Am Acad Orthop Surg 12:371-5. 2004 - Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolismPaul M Ridker
Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston 02215, USA
N Engl J Med 348:1425-34. 2003..0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio... - A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgeryAlexander G G Turpie
Department of Medicine, Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada
J South Orthop Assoc 11:182-8. 2002..4%. The overall incidence of clinically relevant bleeding was low and did not differ between the two groups. The benefit of fondaparinux was consistent across all types of surgery and all subgroups... - Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studiesWilliam D Fisher
McGill University Health Centre, 1650 Cedar Avenue, Montreal, Quebec, H3G 1A4, Canada
Thromb Haemost 97:931-7. 2007..Overall, rivaroxaban total daily doses of 5-20 mg had the most favorable balance of efficacy and safety, relative to enoxaparin, for the prevention of VTE after major orthopaedic surgery... - Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgeryWolfgang Mueck
Clinical Pharmacology, Bayer HealthCare AG, Aprather Weg 18a, Wuppertal, Germany
Clin Pharmacokinet 47:203-16. 2008.... - Two naturally occurring mutations on FVII gene (S363I-W364C) altering intrinsic catalytic activityFlora Peyvandi
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
Thromb Haemost 88:750-5. 2002.... - Venous thrombosis in the elderly: more questions than answersRoy L Silverstein
Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Blood 110:3097-101. 2007